Please read these articles
http://boards.fool.co.uk/Message.asp?mid=7842473

http://www.advfn.com/cmn/fbb/thread.php3?id=3982666

http://www.medisys-group.com/Prelims_5_061202-1.pdf'

http://www.safetysyringesplus.com/info.htm

This has massive potential from products other than FUTURA which if it takes off will be the iceing on the cake.Let me give you the highlights from this Mays interims;

Financial Highlights

Financial performance improved significantly:

* Turnover increased by 9% to #20.1 million (2002: #18.4 million)

* Product sales increased by 25% on a constant US dollar exchange rate basis

* Earnings before interest, tax, depreciation and amortisation was #0.3
million (2002: EBITDA loss of #7.0 million, before exceptional items, as
restated)

* Gross margin 37% (2002: 33%)

* Selling, distribution and administration costs reduced to #4.8 million
(2002: #7.4 million before exceptional items)

* Profit before amortisation and research and development expenditure
#2.6 million (2002: loss of #0.8 million before exceptional items)

* Research and development expenditure #3.0 million (2002: #7.1 million,
as restated)

* Operating loss #1.3 million (2002: #9.2 million, before exceptional
items, as restated)

* Loss before tax #1.6 million (2002: #9.2 million, before exceptional
items, as restated)

* Loss per share 0.58p (2002: 2.58p, before exceptional items, as
restated)

Product Highlights

* Sales of existing products in line with expectations

- Sales of Assure range increased to #6.9 million (2002: #5.6 million)

- QuickTek sales to mail order market segment #2.6 million

- Sales of Futura Safety Scalpel #1.0 million in period

- Sales of Advance system #0.5 million in period

* Futura Safety Syringe and Flight disposable blood glucose monitoring
system remain on track for mid-2003 market launch

* Development of Spear capillary fill bio-sensor strip proceeding to
schedule.

Pretty impressive eh !!

Now since this we have had;

FDA approval for Hypogaurd

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=4778825&symbol=LSE%3AMDY

Futura passing final quality tests with Smiths

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=5023328&symbol=LSE%3AMDY

A partnership with Walmart for Flight

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=5194692&symbol=LSE%3AMDY

Launch of Spear

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=5250424&symbol=LSE%3AMDY

Medisys "buy"

Monday, September 29, 2003 8:28:27 AM ET
Dryden Financial

LONDON, September 29 (New Ratings) Analyst I Broadhurst of Dryden Financial issues a "buy" rating on Medisys (MDY.L).

2003 New Ratings

Now this looks to me a company growing rapidly.The more I look into MDY the more confident I become of the potential rewards.These will not be instantaneous but will come over a period of time.Look at the turnaround in those figures posted above.Now that was in a recession.

http://www.charles-stanley.co.uk/content/SMI_oct03.pdf (see page 4)

http://www.research.reuters.co.uk/Research/Earnings.asp?ticker=MDY.L&country=GB&mxid=100068815&companyName=MEDISYS+PLC&sym=RE
VERY IMPORTANT MESSAGE TO ALL BUYERS/HOLDERS - PLEASE LISTEN

http://www.wallstreetreporter.com/profiles/Medisys.html

ANY STOCK THAT TRADES HUGE VOLUME AT HIGHER PRICES SIGNALS THE DISTRIBUTION PHASE."

When there was less volume, the price was lower. Professionals were
accumulating. After the price runs, the volume increases. The professionals bought low and sold high. The amateurs bought high (and will soon enough sell low). In older books about market manipulation and stock promotion, which I've recently studied, the mark-up price referred to THREE times higher than the floor. The floor is the launch pad for the stock. For example, if one looks at the stock price and finds a steady flat line on the stock's chart of around 10p , then that range is the FLOOR. Basically, the mark-up phase can go as high as the market manipulator is capable of taking it. From my observations, a good mark-up should be able to run about five to ten times higher than the floor, with six to seven being common. The market manipulator will do everything in his power to keep you OUT OF THE STOCK until the share price has been marked up by at least two-three times, sometimes resorting to "shaking you out" until after he has accumulated enough shares. Once the mark-up has begun, the stock chart will show you one or more spikes in the volume -- all at much higher prices (marked up by the manipulator, of course).

I think we all have to agree that these market manipulators have a damn sight more information than we do. There is nothing to say that they know maybe of impending news and hence that scenario works. What we have seen is a floor established and people wanting to get their money out as other opportunities come along. This is all well and good and I respect that. Some however are keen to accumulate stock at this level as they know that if the management do actually deliver there will be a very strong and sharp rise in the share price.


ADVFN seems to attract traders wanting a 10-20%+ return on their money in a few days. It does not, to some extent, attract investors who are prepared to lock away their shares for a year or two and hopefully reap much better rewards. Go back to the likes of YOO,AHT or CS. and think what mountain of cash you would be sitting on now had you bought and held !

Everyone slags certain stocks off and deservedly MDY has attracted alot of attention due to the recent departure from Smiths.Time is moving closer to the timescales discussed by the MDY management and it is now time to see if they can actually deliver on their promises this time round.

Nomura have given fair value at 20p without Flight or Futura. Now I am quite happy to sit this one out and wait for the long awaited iceing on the cake wether it is delivered in a month or three as I know when we get it we will all be very very happy investors.

Very interesting development on BBC website.Could hold serious potential for MDY.

Very interesting development on BBC website.Could hold serious potential for MDY.
http://news.bbc.co.uk/1/hi/health/3505777.stm

MDY had big sells today can anyone let me know why?has i have not heard anything for a while?????????

pc4900074200 - 26 Feb'04 - 17:32 - 3768 of 3770


Just reading the 2003 Annual reports & accounts.
On page 42 I see that Medisys and Smiths have
agreed to meet and a forum is provisionally set
for March. They will attempt to resolve their claims.

More good news on the way!!

pc

Interesting !!!

This share is an absolute disaster area, I sold my holding last April at 13.87, and look at the price now! " More good news on the way" what are you talking about Happy? Another 12 months waiting for something positive to happen?

Suggest you read the last set of results in more detail then !

1.EBITDA POSITIVE

2.LAUNCH OF FLIGHT TO WALMART

3.LAUNCH OF FUTURA SYRINGE

The price represents the current sentiment which when it changes will be relected.

Medisys is it on the way up on this news:-Medisys, Smiths confirm termination of Futura Safety Syringe distribution deal
AFX


LONDON (AFX) - Medisys PLC and Smiths Group PLC said their dispute concerning distribution of the Futura Safety Syringe has been resolved to the satisfaction of both parties and the Distributorship Agreement between them has been terminated.

Medisys confirms that it continues to market its Futura Safety Syringe product in the US and other markets.

newsdesk@afxnews.com

slm/

OR IS IT ON THE WAY DOWN ON THIS NEWS

Medisys says Hypoguard, 3 others named in complaint for patent infringement
AFX


LONDON (AFX) - Medisys PLC said Hypoguard, its diagnostics division, has been named as one of four defendants in a complaint for patent infringement made by Roche Diagnostics Corp in the US.

The other named defendants are Apex Biotechnology Corp, Medline Industries, Inc and Home Diagnostics Inc.

The complaint, in the Indianapolis Division of the US District Court, alleges that the use and sale of the Assure family of blood glucose monitoring products infringe two patents owned by Roche.

The Assure products are made and supplied to Hypoguard by Apex under a supply and distribution agreement. This agreement includes an indemnity, given by Apex to Hypoguard, for liability arising from the Assure products infringing the intellectual property of a third party, Medisys said. Apex confirmed that it will stand behind such indemnity in relation to Roche's complaint, Medisys added.

Hypoguard said it is investigating the validity of the patents and will respond to the complaint once it has completed its probe.

newsdesk@afxnews.com

jc

No matter which one you choose, today saw a 7.3% rise with trades of 18 or so million 12.5million buys to 8.2 million sells. This company would appear to be in the wars and not only needs an injection but some protective headgear and body armour to avoid being too hurt from the head,body, heady blows. One thing after another seems to halt its recouperation. It would seem that it is a cheap stock at this time, just a little get well note from the injured party would let us know that it is on the road to recovery and would be well appreciated by its 'family' of shareholders. Good luck DYOR.

Happy get a life and put your money in to something else.

Scottie SIT there's a good BOY !

SOme people dont fully understand the potential returns on offer here !

Scottie, if you're not into this, why waste your time (and ours) posting useless statements?

This is why people will invest in MDY !

Jenniferzz - 6 Mar'04 - 10:26 - 5093 of 5096


LONDON (AFX) - Tadpole Technology PLC year to September 30 2003
Sales on continuing ops - 3.57 mln stg vs 1.84 mln
Pretax loss - 9.57 mln stg vs loss 11.14 mln
Loss per share - 4.3 pence vs LPS 5.7

TAD MKT CAP 54 Million, sales 3.57 million, 9.57 million loss

LONDON (AFX) - Medisys PLC year to September 30 2003
Sales - 39.59 mln stg vs 35.72 mln
Pretax loss before exceptionals - 2.50 mln stg vs loss 19.58 mln
Pretax profit before exceptionals and goodwill - 4.1 mln stg vs loss 2.5mln
Pretax loss - 5.68 mln stg vs loss 32.99 mln
Operating loss before exceptional - 1.99 mln stg vs loss 19.52 mln
Operating loss - 5.51 mln stg vs loss 31.82 mln
EBITDA - 1.1 mln stg vs loss 14.8 mln
Loss per share before exceptionals - 0.97 pence vs LPS 5.37
Loss per share - 1.78 pence vs LPS 8.85

MDY MKT CAP 42 Million, sales 39.59 million, EBITDA positive

Compare TAD or a mulititude of others with MDY and MDY is far better
value and any growth story scenario is dismissed and should the Queens huskies fart in her lounge at the weekend then this is certain to result in a mark down in the MDY share price. The value of this company will be borne out and a significant higher value or a takeover of the business is inevitable.

According to the last paragraph look for some more new products to boost sales later !!

New Retractable Syringe from Medisys


Pharmacy Today

The UK company Medisys, in an effort to conform to new US laws protecting medical staff from needle-stick accidents, has developed a hypodermic syringe with retractable needle. Medisys' Futura syringes have an automatic retractable needle that retracts into the syringe when the hypodermic plunger is fully depressed. They are expected to be on the market later this year.


Stricter US laws are a reaction to the 800,000 needle-stick injuries that occur annually in the US, all of which have the potential of spreading the human immunodeficiency virus (HIV) or hepatitis. It is increasingly likely that these stricter laws and regulations will be replicated in Japan, Singapore, and other countries.


The retractable technology of the Futura syringe is the core of Medisys' safety development measures, which are exploited in a number of other products. The company also expects to release a safety catheter with a retractable needle mechanism within the next 18 months.

Shipments to Walmart beggining !!

Parlex To Add Greater Value On Computer & Medical Projects

METHUEN, Mass.--(BUSINESS WIRE)--March 3, 2004--Parlex Corporation announced today that two major customers have qualified Parlex to provide additional assembly services on flexible circuits they currently supply. As a major supplier to the inkjet printer market, Parlex will now place surface mount components on many of the products it manufactures. Component attachment will utilize Parlex's patented, lead free adhesive, Polysolder(R). Based on customer projections, this additional scope could add up to $4 million to its computer segment sales over the next 12 months. In the medical market, Parlex has been a supplier of glucose monitoring test strips for the past 15 months. Our customer, Hypoguard, the diagnostic division of Medisys PLC, has qualified Parlex to produce a fully integrated glucose monitoring system with 100 pre-calibrated test strips in a disposable pre-loaded meter. Parlex anticipates that this transition will more than double the unit value of our product. Shipments are scheduled to commence in the next few weeks.


Peter J. Murphy, Parlex President and CEO stated, "It is clear that moving up the value chain should accelerate revenue growth and strengthen relationships with our customers. We believe that our ability to offer the widest range of flexible interconnect products, including value added products, will enhance our position in the marketplace. The Company currently has an added value element on approximately 30% of our business; our goal is to increase this to over 50% by year end."

About Parlex Corporation

Parlex Corporation is a world leader in the design and manufacture of flexible interconnect products. Parlex produces custom flexible circuits and laminated cables utilizing proprietary processes and patented technologies, which are designed to satisfy the unique requirements of a wide range of customers. Its manufacturing facilities are located in the United States, China, Mexico and the United Kingdom.

The foregoing contains certain forward-looking statements. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of various factors beyond its control, including economic conditions in the electronics industry, particularly in the principal industry sectors served by the Company, changes in customer requirements and in the volume of sales to principal customers, competition and technological change. For a detailed discussion of these and other cautionary statements, please refer to Parlex's filings with the Securities and Exchange Commission.

A great post worth sharing !

Author german bite View Profile | Add to favourites | Ignore
Date posted today 12:26
Classification Comment
Subject: My Reasons
Opinion Strong BUY
Recommendations This message has been recommended 10 times, including by you
Message


********************

Those of us that are involved with the stock market know that is not an exact science in so far as valuations v's the share price of a quoted company are concerned. Indeed we all know of companies that over the years have been OVERVALUED or UNDERVALUED in relation to the company/underlyeing business a direct opposite to what the share price (market cap) was saying at the time.

I start off by saying that some of the "previous" managements decisions/deals/rational "appear" to have been, to put it mildly, very poor, but I HONESTLY BELIEVE those days are behind us and the company under the CEO David Conn, is now in good hands.

So lets have a look at MEDISYS basic core business which it SHOULD be VALUED on today:

TURNOVER: 2001 2002 2003

20.9mm 35.7m 39.1m

All well and good but what about costs such as Admin,Sales and Distribution?

SALES and DISTRIBUTION COSTS:

27% of REVENUE 2001 20% of REVENUE 2002 12% of REVENUE 2003

ADMIN COSTS:

21% of REVENUE 2001 18% of REVENUE 2002 13% of REVENUE 2003

RESEARCH and DEVELOPEMENT:

23% of REVENUE 2001 38% of REVENUE 2002 12% of REVENUE 2003

NOTE:As you can see a MASSIVE amount of money was spent on R and D (2002)mainly due to getting the FUTURA SAFETY SYRING and NEWTEK (Wal Mart)monitor ready.Now that they are ready for market less R and D expenditure is incured as you can see by the fall in 2003!
____________________

Worth noting at this point that Diabetes Monitors are "sold at a loss" by all companies and the profit is gained from subsequent sales of the "test strips".So if a NEW monitor is brought to market,innitialy it hits costs for little return.HOWEVER the new monitor we have invented and are bringing to market via WAL MART is an ALL in ONE that has test strips built in so will be sold with an IN BUILT PROFIT MARGIN at point of sale.

______________________

Were are our markets:?

TURNOVER:

UK 2.944m 2001 1.53m 2002 0.433k 2003

US 26.49m 2001 34.11m 2002 36.74 2003.

OTHER 0.464k 2001 0.730k 2002 1.943m 2004.

From the above I looked at the LOSS on the UK business of 13.37m in 2002 and a LOSS of 3.451m in 2003 to ALLOW for the possibility that we will, at some point, become just a USA company either quoted on the NasdaQ or simply bought out by a USA based company.

CLASS of BUSINESS TURNOVER:

DIAGNOSTICS : 23.17m in 2002 31.12m in 2003.

HEALTH SAFETY PRODUCTS 4.027m in 2002 3.86m 2003.

This gives us our "core" market.I would like to point out at this stage the reasons I am not "worried to death" about ROCHE.

Medisys have declared they are indemnified by Apex,however we do not know at this stage how "wide"

Make no mistake it is not ideal.From this point we have to make some MASSIVE assumptions and other less so large ones!

Firstly, there has to be MERIT in ROCHES claims.

Secondly they have to prove this.

Thirdly, they have to WIN in a court of law.

So ASSUMING the worst, MEDISYS have to stop selling the ASSURE meters,well we DO HAVE OTHERS but how hard is it to replace a best seller??

This is a run down of MEDISYS previous FLAGSHIP betselling monitor the SUPREME that is casually and very successfully being replaced by our other monitors.

SALES of SUPREME:

2001 10.5m 2002 7.6m 2003 4.2m

My point being, if MEDISYS can REPLACE the above monitor so successfully in such a relatively "short" time span when there is no RUSH, imagine what they could do if they needed to "transfer" old ASSURE users over to NEWTEK,QUICKTEK or ADVANCE meters!

To some up the company under David Conn have cleaned up the books with MASSIVE write offs the put a line under past "management mistakes"

They have REDUCED Sales and Distribution costs:

They have REDUCED Administration costs:

They have REDUCED R + D costs, yet still keep a healthy spend of approx (on my expected 2004 numbers) of around 11% of TURNOVER,to show that more NEW PRODUCTS are in the pipeline, after all this is the FUTURE REVENUE.

They have INCREASED Turnover.

They have increased Gross Profit

They HAVE IMHO already taken us (as results will prove interims March 2004)into MAIDEN profit.

This is without ONE PENNY of revenue from either the FUTURA SAFETY SYRINGE or NEWTEK.
**************

I FULLY take on board the markets at this moment in time do not like MEDISYS or its past management mistakes or unforfilled promises but there WILL come a point were the UNDERLYING real tangible proven (in the accounts) VALUE and WORTH of this company will shine like a beacon for anyone that cares to look.

If the institutions choose to continue to ignore us and refuse to walk toward the light, then there is a VERY REAL chance IMHO of EITHER a TAKE OVER, MBO or going private or as mentioned before QUITING the UK altogether for the US markets who are more aquainted with our HYPOGUARD arm/brand anyway.

How base market place is growing all over the world.Our REACH will grow along with Wal Mart (and other partnerships we "actively seek")and barring an overnight "cure" for diabetes (equal too petrol not being needed overnight, so Shell better watch out!)no matter what happens to an extent to acconomies,DIABETES is growing and the need for our products grows by the day too.

What ever happens,I HONESTLY believe that my INVESTMENT in this company will REPAY me handsomely in the FUTURE for my faith and patience.


GB (Lisa279)

Medisys shares jump on syringe launch
Mon 22 March, 2004 08:56
RELATED REPORTS
MDY.L Profile Report
Business description, 3yr and interim financials, key stats/ratios & analysis.
| 12 pages | 10 | Details


LONDON (Reuters) - Shares in Medisys have leapt as much as 26 percent after the medical devices firm said it had launched its long-delayed Futura Safety Syringe in the United States and received its first big order.

At 8:35 a.m. on Monday, the shares MDY.L were up 23.8 percent at 13 pence, off an early high of 13-1/4p and valuing Medisys at about 53 million pounds.

The Futura Safety Syringe, whose needle retracts to stop hospital staff from pricking themselves, was originally planned for launch more than two years ago, but was dogged by testing delays and an argument between Medisys and the firm's original distribution partner, Smiths Group SMIN.L .

Medisys sacked Smiths in September after that firm's chief executive, Keith Butler-Wheelhouse, was quoted in a newspaper as saying he had "almost given up" on the Futura Safety Syringe.

Medisys said it had launched the syringe through its own 40 person sales and marketing team and won its first big order from an unnamed medical products distributor in the United States.

It also said it was continuing to explore a potential major distribution partnership.

Bet you wish you hadn't sold out now chickens!!!

Onwards and upwards with futura leading the way.

LOL !

I'm am actually now getting very excited by MDY ! Why ?

Well when the stock market was down heavily the share was trading as high as 26p.News of the split with Smiths and the patent problem have driven the price down 50% !

The Futura issue which everyone has been waiting for has now been resolved and lets just anticipate that the news on the patent front is unfounded.During this downtime we also went EBITDA positive.

Now those factors alone should really see us moving back to the recent highs if not higher and with the possibility of additional good news we could all be looking at a very Merry Christmas.